Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study

ARTAÇ, MEHMET; COŞKUN, HASAN; Korkmaz, Levent; Kocer, Murat; Turhal, Nazim; ENGİN, HÜSEYİN; Dede, Isa; PAYDAŞ, SEMRA; Oksuzoglu, Berna; Bozcuk, Hakan; DEMİRKAZIK, AHMET

doi:10.1016/j.clgc.2016.04.021

Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study

Atıf İçin Kopyala

ARTAÇ M., COŞKUN H. Ş., Korkmaz L., Kocer M., Turhal N. S., ENGİN H., ...Daha Fazla

CLINICAL GENITOURINARY CANCER, cilt.14, sa.4, 2016 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 14 Sayı: 4
Basım Tarihi: 2016
Doi Numarası: 10.1016/j.clgc.2016.04.021
Dergi Adı: CLINICAL GENITOURINARY CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Anahtar Kelimeler: Cytokine therapy, VEGF inhibitors, Progression free survival, Sorafenib, Sunitinib, ENDOTHELIAL GROWTH-FACTOR, SUNITINIB, INTERLEUKIN-2, THERAPY, SU11248
Çukurova Üniversitesi Adresli: Evet

Özet

Survival outcomes of interferon-alfa and tyrosine kinase inhibitors for 104 cases of metastatic renal cell carcinoma were included in this study. First-line interferon-alfa treatment before tyrosine kinase inhibitors had an additive survival affect.